Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

Open access

Abstract

We analyzed the presenting features and survival in 1689 patients with multiple myeloma aged younger than 50 years compared with 8860 patients 50 years of age and older. Of the total 10 549 patients, 7765 received conventional therapy and 2784 received high-dose therapy. Young patients were more frequently male, had more favorable features such as low International Staging System (ISS) and Durie-Salmon stage as well as less frequently adverse prognostic factors including high C-reactive protein (CRP), low hemoglobin, increased serum creatinine, and poor performance status. Survival was significantly longer in young patients (median, 5.2 years vs 3.7 years; P < .001) both after conventional (median, 4.5 years vs 3.3 years; P < .001) or high-dose therapy (median, 7.5 years vs 5.7 years; P = .04). The 10-year survival rate was 19% after conventional therapy and 43% after high-dose therapy in young patients, and 8% and 29%, respectively, in older patients. Multivariate analysis revealed age as an independent risk factor during conventional therapy, but not after autologous transplantation. A total of 5 of the 10 independent risk factors identified for conventional therapy were also relevant for autologous transplantation. After adjusting for normal mortality, lower ISS stage and other favorable prognostic features seem to account for the significantly longer survival of young patients with multiple myeloma with age remaining a risk factor during conventional therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-03-081018

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 253

Metadata

Authors
Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., Westin, J., Harousseau, J.-L., Beksac, M., Boccadoro, M., Palumbo, A., Barlogie, B., Shustik, C., Cavo, M., Greipp, P. R., Joshua, D., Attal, M., Sonneveld, P., & Crowley, J.
Affiliations
  • Wilhelminen Hospital (AT)
  • Cedars-Sinai Medical Center (US)
  • Cancer Research And Biostatistics (US)
  • Department of Hematology, University Hospital, Malmö, Sweden;
  • Mayo Clinic (US)
  • Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d' Investigacious Biomediques August Pi i Sunyer, Barcelona, Spain;
  • Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ;
  • National and Kapodistrian University of Athens (GR)
  • Department of Medicine, Nagoya City Midori General Hospital, Nagoya, Japan;
  • University Hospital of Salamanca, Salamanca, Spain;
  • Skåne University Hospital (SE)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Department of Microbiology and Clinical Microbiology, Ankara University School of Medicine, Ibn-i Sina Hospital, Ankara, Turkey;
  • University of Turin (IT)
  • University of Arkansas for Medical Sciences (US)
  • McGill University (CA)
  • Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy;
  • Royal Prince Alfred Hospital (AU)
  • Hôpital Purpan (FR)
  • Erasmus MC (NL)
Venue
Blood
Published
2008-04-15
Volume
111
Issue
8
Pages
4039-4047
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2137040543
Cited by
230
References
40
Citations by year
2026: 1 · 2025: 13 · 2024: 11 · 2023: 21 · 2022: 11 · 2021: 9 · 2020: 14 · 2019: 22 · 2018: 9 · 2017: 14 · 2016: 18 · 2015: 13 · 2014: 12 · 2013: 15 · 2012: 9
FWCI
7.57
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Funders
National Cancer Institute
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
Keywords
multiple myeloma, young patients, age as risk factor, survival, prognostic factors, International Staging System, Durie-Salmon stage, autologous stem cell transplantation, high-dose therapy, conventional therapy, C-reactive protein
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, International Cooperation, Male, Middle Aged, Multiple Myeloma, Prognosis, Risk Factors, Multivariate Analysis, Survival Analysis, Age Distribution, Cytogenetic Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. https://app.cochat.ai/papers/10.1182/blood-2007-03-081018
The paper
Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., Fonseca, R., Dimopoulos, M., Shimizu, K., San Miguel, J., Westin, J., Harousseau, J.-L., Beksac, M., Boccadoro, M., Palumbo, A., Barlogie, B., Shustik, C., Cavo, M., Greipp, P. R., . . . Crowley, J. (2008). Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. https://doi.org/10.1182/blood-2007-03-081018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.